Please assess the completion status of the following clinical trial:

Trial Title: A Pilot Study to Test Activity of Antimalarial Drugs Against an Induced Malaria Infection in Healthy Volunteers

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: None
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1/PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Males aged 18-45 years who do not live alone~* BMI within 18-30~* Understand the procedures and risks involved~* Contactable for the duration of the study~* Non-smokers and in good health~* Good venous access~Exclusion Criteria:~* History of malaria~* Been in a malaria-endemic country within 12 months~* Evidence of cardiovascular risk~* Splenectomy~* History of severe allergic reactions after vaccination of infusion~* Any serious chronic illness~* Inherited genetic anomaly~* Any volunteers wishing to donate blood to the blood bank in the future~* Retinal or visual field changes~* Diagnosis of chronic severe psychiatric condition~* Hospitalisation within 5 years for psychiatric illness, suicide attempt or danger to self or others~* Receiving psychiatric drugs (some exceptions)~* Known QTc prolongation~* Family history of cardiac anomalies~* Recent or current therapy with an antibiotic or drug with potential antimalarial activity~* Known hypersensitivity to artemether or lumefantrine, atovaquone or proguanil hydrochloride or any of the excipients~* Concomitant use of any drug which is metabolised by the cytochrome enzyme CYP2D6 OR drugs that are known to prolong the QTc interval~* Use of corticosteroids, anti-inflammatory drugs, any immunomodulators or anticoagulants. Currently receiving or have previously received immunosuppressive therapy, including systemic steroids including ACTH or inhaled steroids in dosages which are associated with hypothalamicpituitary- adrenal axis suppression such as 1mg/kg/day of prednisone or its equivalent or chronic use of inhaled high potency corticosteroids~* Presence of acute infectious disease or fever~* Evidence of acute illness within the four weeks before trial prior to screening~* Significant intercurrent disease of any type, in particular liver, renal, cardiac, pulmonary, neurologic, rheumatologic, or autoimmune disease by history, physical examination, and/or laboratory studies including urinalysis~* Alcohol consumption greater than community norms~* A history of drug habituation, or any prior intravenous usage of an illicit substance~* Medical requirement for intravenous immunoglobulin or blood transfusions~* Participation in any investigational product study within the 8 weeks preceding the study~* Participation in any research study involving significant blood sampling, or blood donation to a blood bank during the 8 weeks preceding the study~* Have ever received a blood transfusion~* Positive test for HIV, Hepatitis B, hepatitis C, Human T-cell Lymphotropic Virus I \& II (HTLVI \& HTLVII), and syphilis~* Any clinically significant biochemical or haematologic abnormality (Hb must be ≥13.5g/dL)~* Ingestion of any poppy seeds within the 48 hours prior to the screening blood test~* Detection of any recreational drug listed in the urine drug screen

- Gender: MALE
- Minimum Age: 18 Years
- Maximum Age: 45 Years
- Healthy Volunteers: t

Study Arms:
- Artemether/lumefantrine tablets (Type: ACTIVE_COMPARATOR): Artemether (20 mg) and Lumefantrine (120 mg) tablets: Four tablets taken as a single dose twice a day with fatty food for three days (total dose of 24 tablets in 6 doses) on days 6-8
- Atovaquone/Proguanil HCl tablets (Type: ACTIVE_COMPARATOR): Atovaquone (250 mg) and Proguanil HCl (100 mg) tablets: Four tablets taken as a single dose daily for 3 days (total dose of 12 tablets) on days 6-8

Based on this trial design, predict the completion outcome and termination type (if applicable).